A
trial natriuretic factor (ANF) is a peptide hormone produced principally by the heart, which has natriuretic, diuretic, and vasodilatory properties.1-3 Because ANF has important volume-regulatory characteristics it is postulated to play a role in volume homeostasis under normal conditions and in pathophysiological states such as congestive heart failure (CHF).3 It is well recognized that plasma ANF concentrations are elevated in patients with CHF,4-7 and the extent of elevation has been shown to correlate positively with atrial pressure. 5, 6 Plasma ANF concentrations may change within minutes of alterations in atrial pressure, 5, 6, [8] [9] [10] and the diuretic response to intravenous infusion of ANF occurs rapidly.7 These observations are consistent with a model in which ANF is stored in atrial tissue for rapid release and in which ANF functions as a promptly acting modulator of acute changes of intravascular volume.
The role of ANF in chronic heart failure is less well understood. Because symptomatic CHF may ensue despite the increased plasma ANF concentrations, some investigators have suggested that cardiac production of ANF may become inadequate in severe heart failure, ie, that there is a "relative deficiency" of ANF. In the rat, acute hypertensive stress"1,'2 or myocardial infarction13"14 results in decreased atrial ANF tissue concentration. Chronic hemodynamic stress such as that in the spontaneously hypertensive rat'5-'7 or the cardiomyopathic hamster'8-2' also results in decreased ANF tissue levels. In contrast to these data suggesting depletion of stored ANF in the atrium, other studies show heart failure to be characterized by stimulation of ANF atrial and ventricular synthesis.12,14,20-32 Nevertheless, integrated physiological studies in animals are consistent with the concept that the effectiveness of ANF in modulating intravascular volume in chronic heart failure may be diminished. Using the canine rapid ventricular pacing model of acute and chronic heart failure, Redfield and coworkers33 demonstrated that chronic heart failure animals stressed with volume expansion showed no further increase in plasma ANF levels. Volume loading studies in chronic human heart failure have shown conflicting results, showing no increase in plasma ANF or mixed responses.34 '35 Taken together, all of these findings support the hypothesis that a state of maximal ANF release may be achieved in heart failure. Progressive fluid retention in chronic heart failure could, therefore, be a consequence of ANF depletion, inadequate production of ANF, or altered ANF processing and release from the myocardium. 36 In contrast to animal models, few data are available on ANF concentration in human myocardium, and those that have been reported are inconsistent. Immunohistochemical staining of human tissue obtained by endocardial biopsy or necropsy indicates that atrial ANF is present in heart failure, and ANF staining in ventricular tissue increases during heart failure.2027 '31 The ANF content of failing human myocardium obtained at necropsy reflected no change in atrial concentration but an increase in left ventricular ANF concentrations. 28 Other studies using a small number of human tissues obtained by surgery, necropsy, and endomyocardial biopsy have suggested that failing hearts had increased atrial and ventricular ANF concentrations.29 Surgical specimens of human atrial tissue from failing hearts have been reported to contain high ANF concentrations, but normal control tissues were either not available37 or were obtained from necropsy hearts.38
In addition to the conflicting reports on ANF tissue concentrations in CHF is the inadequate characterization of the molecular forms of ANF in CHF. ANF exists in three forms: the prohormone y-ANF (amino acids 1-126), the circulating peptide a-ANF (amino acids 99-126), and 3-ANF (a 56-amino acid antiparallel dimer of a-ANF).37-40 Membrane proteases cleave a-ANF from y-ANF during release. [41] [42] [43] In normal subjects without CHF, a-ANF is the principle circulating form, but small amounts of j3-and y-ANF may be found in plasma; the N-terminal 1-98 ANF fragment can also be detected.4445 Although biological activity resides in the circulating a-ANF form under normal circumstances, ,3-ANF may be converted to a-ANF in plasma and has been shown to have biological effects when administered intravenously to normal human subjects.46 The biological activity of the ,3-ANF dimer is potentially important since, in chronic human heart failure, the plasma concentrations of a-, 3-, and y-ANF subspecies are increased.4445'47-49 Analysis of right atrial tissue samples obtained from diseased hearts at surgery suggests that there may be increases in a-and ,3-ANF concentrations29,37,38; data on right atrial y-ANF concentrations are inconsistent.29 '38 The current study was therefore designed to address the limitations and inconsistencies of previous reports of human myocardial concentrations of total ANF and its molecular forms in chronic heart failure. We In two cases, the heart was not used because of concern that the organ donor might have an active infection. In one case, the heart was not used because of suspicion of right ventricular contusion; subsequent histological assessment of tissue from this heart, however, showed normal myocardium. These patients did donate other organs (kidneys in all cases, with variable numbers of patients donating aortic homografts, livers, and corneas). These normal donors ranged in age from 2 to 42 years (mean, 24.3±0.9). Causes of death were motor vehicle accident (n=4), head trauma (n=2), aspiration pneumonia (n=1), circulatory collapse associated with acute alcohol intoxication (n= 1), and uncertain cause of death (n=4). Conventional transplant practice is to harvest other organs first so that the heart maintains normal circulation to them. Tissue samples were obtained from these normal hearts within 10 minutes of the completion of the harvest of noncardiac organs and were frozen at -80°C for subsequent radioimmunoassay. Heart weights were not obtainable on these specimens because the hearts were not excised. Samples were obtained from all anatomic sites in 10 hearts and from the ventricles only in 2 hearts.
Extraction ofANF and Radioimmunoassay
Extraction of ANF and radioimmunoassay were per- Comparison of normal and failing hearts. The most striking difference between the total ANF concentrations in normal and failing myocardium was in the atria. In the LAA the ANF concentration increased from 188.4±50.2 ng/mg protein in the normal heart to 972.7±207.3 ng/mg protein in the failing heart (P<.001). In the LA free wall it increased from 2.6+0.5 to 961.4±433.7 ng/mg protein (P<.001). In the RAA, the concentration tended to increase from 72.6±12.9 in failing hearts, therefore, a marked increase in total ANF is observed in atrial tissues, with the greatest proportional increase being in the free wall of the atria. In the normal heart, the ANF concentration is highest in the atrial appendages and much lower in the rest of the atrium. In the failing heart, the ANF concentration increases 5-to 10-fold in the atrial appendages and 200-to 370-fold in free wall atrial tissue.
By contrast, tissue ANF concentrations remained low in the failing right ventricle (4.5±1.3 ng/mg protein) and were not different from concentrations in the normal RV (3.2±0.4 ng/mg protein) (P=.8). In the left ventricle, the ANF concentration, 12.7±6.7, was not significantly greater than that in the normal left ventricle, 3 .7±0.5 ng/mg protein (P=.9). However, as can be observed in Table 2 , there was variability in RV and LV concentrations, with several individual failing hearts showing substantially greater ventricular concentrations of ANF (ie, patients 4, 5, and 9).
Molecular Forms ofANF in Cardiac Tissue
Normal hearts. The concentrations of y-, 13-, and a-ANF in normal cardiac tissues are presented in Table  3 and Fig 2. In the normal RAA and LAA the y-ANF storage form predominates, and ,3-ANF and a-ANF are also found in lesser but comparable quantities. In the RA, LA, RV, and LV tissues, all three molecular forms are also detectable, although in much smaller quantities. Failing hearts. As described above, the total ANF concentrations in the atrial appendages increase markedly in the failing hearts. Although there was a tendency for all of the absolute concentrations of the molecular forms of ANF to increase in the RAA and LAA (Fig and Table 3 ), there were also shifts in the proportion of the forms in the failing hearts. While there was a modest increment in a-ANF in the RAA and LAA, there were greater increases in y-and 3-ANF forms, particularly in the LAA (P<.01) (Fig 2) . The relative increase in y-ANF is further emphasized in Table 4 , which depicts the increase in the ratio of y-ANF/a-ANF in the failing RAA and LAA tissues.
Similar changes were noted in the right atrium and left atrium. (Fig 2 and Tables 3 and 4) . The absolute concentrations of all ANF molecular forms increased significantly in the failing atria (Ps.01 for each molecular subtype at each atrial anatomic site). All three molecular forms are present, and the ,B-and y-ANF forms predominate in the RA and LA tissues. There is a marked accumulation of y-ANF in the right atrium and left atrium, as shown in Table 4 , where the failing atrial free walls and left atrial appendage have a significantly higher ratio of y-ANF/a-ANF.
In the failing ventricles all three forms are detectable. Compared with normal hearts, there were no significant increases in the absolute concentrations of the ANF forms in failing hearts (Fig 2; Furthermore, in heart failure, the atrial appendages manifest a marked increase in the absolute concentration of the y-and ,B-ANF forms. In the atrial free wall, the absolute concentrations of all three ANF forms are increased in heart failure, with the most marked increases again being in y-and f-ANF. It is of note that the relative proportion of y-ANF increases in failing atrial tissues, resulting in an increase in the ratio of y-ANF/a-ANF. In the ventricles, all three forms are detectable in normal hearts, and the concentrations of ANF forms are not altered in chronic heart failure in most patients.
Data from rodent models have suggested that atrial tissue ANF concentrations are decreased in both subacute13,14 and chronic18-2' circulatory failure as well as during acute," subacute,12 and chronic hypertensive stress.'5-'7 These findings have supported the hypothesis that CHF leads to a depletion of tissue ANF stores and, despite increased plasma ANF concentrations, to a condition in which demand exceeds the production capacity. Attempts to characterize ANF tissue activity in the human heart have been hampered by difficulties in obtaining optimal tissue specimens.
Previous reports derived from diseased human hearts are inconsistent. Tsuchimochi and coworkers2s also ex- Table 3 . (Fig 1) . Several factors could account for these findings including species differences and differences in weeks in rodents).1214,19 '21,23-26 ANF is generated from the prohormone y-ANF (1-126) and is stored in this form in granules in atrial myocytes. 39 The principle circulating form is a-ANF (99-126), and its dimer, p-ANF, may be detectable in small quantities in plasma of some normal subjects.47 All three forms are known to be elevated in plasma in human heart failure, and increases in plasma B3-ANF have been noted in particular.48'49 Our findings show that all three ANF molecular forms are detectable in the normal atrial appendage, atrial free wall, and ventricle. Furthermore, our data demonstrate that human heart failure produces not only increases in total atrial ANF concentrations but also increases in the atrial concentrations of the y-ANF storage form, the (3-ANF form, and the a-ANF form.
These data in fresh tissues are compatible with those of Naruse and coworkers,38 who compared failing atrial myocardium obtained at cardiac surgery with normal necropsy tissues. Of particular interest is the marked increase in the prohormone -y-ANF in severe CHF. The significance of the increase in tissue y-ANF has yet to be elucidated, but such accumulations raise the possibility that chronic CHF may be characterized by impaired conversion of y-ANF to a-ANF. It is also noted that the ratio of a-ANF to 8-ANF in myocardium is lower than the reported ratio of circulating a-ANF to P3-ANF; this may reflect conversion from the 13 to the a form on release into the circulation. 49 The extent to which the myocardium is able to augment ANF production, combined with the wellduration of severe heart failure (years in humans versus known increases in plasma ANF in heart failure, makes it unlikely that the clinical syndrome of human chronic CHF results from an exhaustion of cardiac ANF production capacity. Rather, other factors such as impaired processing of y-ANF to a-ANF, myocyte loss, and diminished renal responsiveness to ANF may all contribute to sodium and water retention in chronic heart failure.756 The ultimate role of ANF in chronic heart failure will also need to be evaluated in the context of our understanding of other natriuretic peptides that are currently being described. 32 Potential problems in data interpretation could arise from the fact that failing hearts came from patients significantly older than the donor hearts. No data are available on the effect of age on myocardial tissue ANF concentration. Failing tissues were obtained from hearts after surgical excision, and failing hearts were removed after patients were placed on cardiopulmonary bypass; it is not known if these maneuvers affect tissue ANF concentrations. Both groups of hearts also experienced a period of several minutes of lack of coronary perfusion, and the effect of this on ANF production and release is unknown.
In summary, the current report of fresh human myocardial tissue indicates that in severe chronic heart failure there is a significant increase in ANF concentration in the appendages and a marked increase in ANF concentration in the atrial free wall. Increases are observed in all ANF forms but particularly in the ,y-ANF precursor form. Thus, heart failure is characterized by increased rather than depleted cardiac ANF concentration.
